Lifesci Capital Comments on Olema Pharmaceuticals, Inc.'s Q3 2024 Earnings (NASDAQ:OLMA)

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Research analysts at Lifesci Capital issued their Q3 2024 earnings per share estimates for Olema Pharmaceuticals in a report issued on Wednesday, May 8th. Lifesci Capital analyst S. Slutsky anticipates that the company will post earnings per share of ($0.52) for the quarter. The consensus estimate for Olema Pharmaceuticals' current full-year earnings is ($2.34) per share.

Several other research firms also recently commented on OLMA. Citigroup began coverage on shares of Olema Pharmaceuticals in a research note on Tuesday, January 30th. They issued a "buy" rating and a $20.00 price target on the stock. Capital One Financial reaffirmed an "overweight" rating on shares of Olema Pharmaceuticals in a report on Thursday, February 22nd. HC Wainwright boosted their price target on Olema Pharmaceuticals from $25.00 to $28.00 and gave the company a "buy" rating in a research note on Thursday. Finally, The Goldman Sachs Group started coverage on Olema Pharmaceuticals in a research report on Tuesday, April 2nd. They set a "buy" rating and a $24.00 price target on the stock. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Olema Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $21.43.

Olema Pharmaceuticals Stock Performance

NASDAQ OLMA traded down $0.52 on Friday, reaching $9.32. The stock had a trading volume of 603,378 shares, compared to its average volume of 675,363. Olema Pharmaceuticals has a 1-year low of $5.02 and a 1-year high of $17.79. The firm has a fifty day moving average of $11.29 and a two-hundred day moving average of $12.81.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last announced its earnings results on Monday, March 11th. The company reported ($0.49) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.49).

Insiders Place Their Bets

In related news, Director Cyrus Harmon sold 25,000 shares of Olema Pharmaceuticals stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $12.41, for a total value of $310,250.00. Following the sale, the director now owns 846,283 shares of the company's stock, valued at approximately $10,502,372.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 65,000 shares of company stock valued at $726,900 in the last 90 days. 23.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Olema Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio bought a new stake in shares of Olema Pharmaceuticals during the 3rd quarter worth $35,000. China Universal Asset Management Co. Ltd. bought a new stake in Olema Pharmaceuticals during the fourth quarter worth about $89,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Olema Pharmaceuticals in the 4th quarter worth about $130,000. SG Americas Securities LLC bought a new position in shares of Olema Pharmaceuticals during the 3rd quarter valued at about $142,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new position in shares of Olema Pharmaceuticals during the 3rd quarter valued at about $164,000. Institutional investors own 91.78% of the company's stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.